NYKD Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Nykode Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.89 |
| 52 Week High | NOK 21.40 |
| 52 Week Low | NOK 1.55 |
| Beta | 1.33 |
| 1 Month Change | 6.25% |
| 3 Month Change | -43.37% |
| 1 Year Change | -84.99% |
| 3 Year Change | -96.53% |
| 5 Year Change | n/a |
| Change since IPO | -85.41% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate
Aug 05
Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 02Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)
Jan 22We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Shareholder Returns
| NYKD | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -4.2% | -3.9% | -2.8% |
| 1Y | -85.0% | -73.8% | -0.8% |
Return vs Industry: NYKD underperformed the Norwegian Biotechs industry which returned -73.8% over the past year.
Return vs Market: NYKD underperformed the Norwegian Market which returned -0.8% over the past year.
Price Volatility
| NYKD volatility | |
|---|---|
| NYKD Average Weekly Movement | 15.7% |
| Biotechs Industry Average Movement | 14.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.9% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: NYKD's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: NYKD's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 185 | Michael Engsig | nykode.com |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10
Nykode Therapeutics AS Fundamentals Summary
| NYKD fundamental statistics | |
|---|---|
| Market cap | NOK 943.07m |
| Earnings (TTM) | -NOK 423.72m |
| Revenue (TTM) | NOK 49.51m |
19.0x
P/S Ratio-2.2x
P/E RatioIs NYKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYKD income statement (TTM) | |
|---|---|
| Revenue | US$4.37m |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.37m |
| Other Expenses | US$41.77m |
| Earnings | -US$37.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 100.00% |
| Net Profit Margin | -855.88% |
| Debt/Equity Ratio | 0% |
How did NYKD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:32 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nykode Therapeutics AS is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Viktor Sundberg | ABG Sundal Collier Sponsored |
| Geir Holom | DNB Markets |
| Patrick Trucchio | H.C. Wainwright & Co. |